US 12,448,352 B2
Beta adrenergic agonist and methods of using the same
Anthony P. Ford, San Carlos, CA (US); Wei Chen, Saratoga, CA (US); David Scott Carter, Sunnyvale, CA (US); and Jiaxin Yu, Foster City, CA (US)
Assigned to CuraSen Therapeutics, Inc., San Carlos, CA (US)
Appl. No. 17/440,705
Filed by Curasen Therapeutics, Inc., San Carlos, CA (US)
PCT Filed Mar. 26, 2020, PCT No. PCT/US2020/024948
§ 371(c)(1), (2) Date Sep. 17, 2021,
PCT Pub. No. WO2020/198466, PCT Pub. Date Oct. 1, 2020.
Claims priority of provisional application 62/934,482, filed on Nov. 12, 2019.
Claims priority of provisional application 62/824,876, filed on Mar. 27, 2019.
Prior Publication US 2022/0169612 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); C07D 209/42 (2006.01); C07D 213/38 (2006.01)
CPC C07D 209/42 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0034 (2013.01); A61K 9/0073 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 25/30 (2018.01); C07D 213/38 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising about 10 pg to 100 mg of a compound having the following structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, as a unit dosage form.